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Abstract
Background: More than 50% of the worldwide cases of hepatocellular carcinoma occur in China, and this
malignancy currently represents the country’s second leading cause of cancer death in cities and the leading cause
in rural areas. Despite recent advances in the control and management of hepatocellular carcinoma within China,
this disease remains a major health care issue. The global HCC BRIDGE study, designed to assess patterns of
hepatocellular carcinoma therapy use and associated outcomes across real-world clinical practice, has recently
been expanded as a national study in China, allowing a detailed analysis of hepatocellular carcinoma in this
important country.
Methods/Design: The global HCC BRIDGE study is a multiregional longitudinal cohort trial including patients
newly diagnosed with hepatocellular carcinoma between January 1, 2005, and June 30, 2011, who are receiving
treatment for hepatocellular carcinoma via sites in the Asia-Pacific, European, and North American regions. The
HCC BRIDGE China national study comprises the portion of the global HCC BRIDGE study conducted within
mainland China. Patients will be followed from time of diagnosis of hepatocellular carcinoma (post-January 1, 2005)
to time of death or December 31, 2011, whichever comes first. Data will be collected on demographic/clinical
characteristics, relevant laboratory values, hepatocellular carcinoma/underlying liver disease treatment, tumor
response, adverse events, hospitalizations, and overall survival. The primary study end point is overall survival;
secondary end points are disease progression, treatment-limiting adverse events, and treatment failure.
Results: At the time of writing, 15 sites have selected for participation across all 7 traditional regions of China
(North, North-East, East, South, South-West, North-West, and Central). The anticipated study population from the
China national study is approximately 9000 patients.
Discussion: Findings from the HCC BRIDGE China national study, the first geographically representative study of
hepatocellular carcinoma in China, will contribute to the understanding of patterns of therapy use and related
clinical outcomes and will provide further information on continuing unmet needs for hepatocellular carcinoma
throughout this important country.
Background
Hepatocellular carcinoma (HCC), one of the world’s
most prevalent and deadly malignancies [1,2], is particu-
larly common in Asia-Pacific countries, with more than
half of all cases occurring in China alone [2,3]. In most
patients, HCC develops in association with liver cirrho-
sis and/or viral hepatitis infection. Indeed, the main risk
factors for the development of HCC among the Chinese
population are the presence of liver cirrhosis and
chronic infection with hepatitis B virus [4]. Other risk
factors include chronic hepatitis C virus infection, a
family history of liver cancer, depression, ingestion of
aflatoxin B1 via contaminated foodstuffs, and excessive
alcohol consumption [4,5].
Current therapeutic options for HCC in China are
varied, with treatment allocation generally dependent on
the patient’s liver function and tumor burden. Com-
monly used therapies include surgical techniques, such
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any medium, provided the original work is properly cited.as liver resection and liver transplantation; interventional
therapies, such as hepatic artery infusion and transcath-
eter arterial chemoembolization; and ablation techniques,
such as anhydrous alcohol injection and radiofrequency
or microwave ablation [6]. Systemic therapy options,
including radiotherapy, immunotherapy, standard che-
motherapy, and traditional Chinese herbal medicines, are
also recommended [6]. In addition, the multikinase inhi-
bitor sorafenib, which has demonstrated a reduction in
death risk among advanced, inoperable HCC patients
with mostly Child-Pugh A cirrhosis [7,8], is approved in
China for treatment of advanced unresectable HCC.
In recent years, the China Ministry of Health has
made great strides in the management of HCC by estab-
lishing it as one of 5 tumors of high national importance
and by initiating a number of primary HCC prevention
activities. These include providing government-funded
HCC screening for persons in high-risk areas (within
the Jiangsu and Guangxi provinces) who are positive for
hepatitis B surface antigen and who have cirrhosis and,
more recently, enacting mandatory hepatitis B virus vac-
cination programs. Despite these advances, HCC
remains a cancer with a high mortality rate and a clear
unmet medical need in China. Based on data from the
Third China National Mortality Survey conducted in
2004/2005, HCC is the second leading cause of cancer
mortality in cities and the leading cause in rural areas
[9]. Moreover, this survey reported an HCC mortality
r a t ei nC h i n ao f2 6d e a t h sp e r1 0 0 , 0 0 0p e r s o n s .W h e n
considering these mortality data, it is important to
acknowledge that they are pooled from individual stu-
d i e ss u p p o r t e db yt h eC h i n aM i n i s t r yo fH e a l t h ,a n d
only represent certain regions of the country. As such,
the reported national mortality rate may not accurately
reflect the true burden of HCC across the country.
Furthermore, given the lack of active surveillance, there
remain many unanswered questions surrounding the
epidemiology and management of HCC in China.
The global HCC BRIDGE study is an ongoing longitu-
dinal cohort trial of patients with HCC in 3 core geo-
graphic regions (Asia-Pacific, European, and North
American) that is designed to (1) evaluate current treat-
ment approaches to HCC and associated clinical out-
comes, and (2) determine the real-world impact on
clinical outcomes of new HCC treatments, such as sora-
fenib, versus other therapies [10]. Recently, the HCC
BRIDGE study was expanded as a national study in
China allowing a specific and more detailed evaluation
of HCC across this important country.
Methods
Study design
The global HCC BRIDGE study is a multiregional longi-
tudinal cohort trial including patients diagnosed with
HCC from January 1, 2005, to June 30, 2011 [10].
Patients enrolled in the study will be followed from the
date of HCC diagnosis to December 31, 2011, or date of
death, whichever comes first. The HCC BRIDGE China
national study comprises the portion of the global HCC
BRIDGE study conducted within mainland China. To
ensure that the national study is geographically repre-
sentative, it was designed to include patients enrolled at
sites from all 7 traditional regions across China (North,
North-East, East, South, South-West, North-West, and
Central).
Study sites
Sites have been selected for inclusion in the China
national study on the basis that (1) they are tertiary care
centers providing surgical and routine follow-up care for
patients with HCC or are oncology centers that care for
these patients; (2) the type and proportion of etiologies
for HCC are consistent with the Chinese national aver-
age; and (3) the HCC screening practices, when used,
are in accordance with Chinese national standards. In
addition, sites may be selected if the patient population
was, on a prior occasion, used to characterize the
Chinese national HCC population for other research
purposes, for example during evaluation of national
HCC incidence/prevalence rates or the establishment of
national HCC staging systems.
Patients
All patients enrolled in the HCC BRIDGE study must
meet 3 key inclusion criteria: (1) diagnosed with HCC
between January 1, 2005, and June 30, 2011, in accor-
dance with American Association for the Study of Liver
Diseases/European Association for the Study of the
Liver guidelines [11]; (2) aged at least 18 years at the
time of HCC diagnosis; and (3) received or receiving
treatment for HCC through a site enrolled in the HCC
BRIDGE trial. Patients participating in other clinical
trials will be included in the study if the patient is
enrolled in a single-arm clinical trial, enrolled in a ran-
domized clinical trial of HCC adjuvant therapy, or was
not selected to receive active treatment in a randomized
clinical trial that was conducted between 2005 and
2007. Any patient whose first active HCC-directed treat-
ment is received via participation in a randomized clini-
cal trial of primary HCC therapy will be excluded from
the current study, since this treatment regimen would
have been determined by a study protocol rather than
by the treating physician. Similarly, patients included in
the China national study who subsequently enroll in such
a trial will be censored from the study at that time point.
Patients with unknown month and year of HCC diagnosis
or of the first visit at the site of inclusion will be excluded.
Furthermore, to preserve regional representation within
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for a particular study site will also be excluded. Finally, in
order to avoid selection bias when the number of eligible
patients at a site exceeds the number allowed according to
study sample size calculations, an enrollment scheme will
be adopted such that the same number of consecutive
patients are enrolled each month. For example, in the first
year of data entry, if a site is to enroll 200 patients,
approximately 17 consecutive patients diagnosed with
HCC will be enrolled in each month. If there are less than
the specified numbers of patients in any given month, we
ask that the corresponding number of extra patients be
enrolled in the following month.
Comparator groups
In order to evaluate the influence of sorafenib on HCC
treatment patterns in China, clinical outcomes will be
compared across 2 periods within the overall study
duration: (1) the period when sorafenib was unavailable
(2005 to 2007) and (2) the period when sorafenib was
available for use (2008 to 2011). These 2 periods will be
differentiated by the first record of sorafenib use at each
site. Patients treated during the period when sorafenib
was not available will act as historic controls and will be
statistically matched within the pool of patient data by
age, sex, Child-Pugh status, and HCC stage to patients
treated with sorafenib between 2008 and 2011. Patients
treated with non-sorafenib therapies during the period
when sorafenib was available will act as concurrent con-
trols and will be used to evaluate characteristics of HCC
patients treated with sorafenib versus other therapies. In
this study, “sorafenib treatment” is defined as the use of
either sorafenib alone or concomitant use of sorafenib
and other pharmacologic agents or interventions within
21 days of each other.
End points
The primary end point will be overall survival (all-cause
mortality); secondary end points will include disease
progression, treatment-limiting adverse events, and
treatment failure (Table 1). Data from these protocol-
defined end points will be used to analyze treatment
patterns and therapeutic outcomes as described in the
following sections.
Data collection
The following data will be systematically collected for all
enrolled patients: (1) date of diagnosis and/or date of
first HCC visit; (2) demographic and clinical characteris-
tics at the time of diagnosis/first HCC visit and at all
occurrences of new treatment intervention during the
study period via medical chart review; (3) data on var-
iants of HCC diagnosis, for example, mixed HCC, fibro-
lamellar HCC, and on the additional diagnosis of
cholangiocarcinoma; (4) data on the use of currently
available HCC treatment approaches during the study
period from medical chart review; (5) data on the use of
new treatments for HCC if they become available and
are used prior to study end; (6) data on hospitalizations,
clinical visits, and visits to other health care profes-
sionals, with collection of hepatic function, tumor
assessments, and laboratory values according to clinical
judgment; and (7) data on method of payment for health
care utilization. All data will be collected retrospectively
and prospectively at study sites in order to account for
patient records over the full duration of the study; data
collection is expected to be complete by June 2012. All
sites will enter data into an electronic data capture sys-
tem developed by Outcome Sciences, Inc. (Cambridge,
MA, USA). Outcome Sciences will manage the data sys-
tem, including monthly data monitoring and cleaning,
site queries, and check of invalid clinical values deter-
mined a priori by study investigators. All data collection
Table 1 Definitions of study end points
Primary end point
Overall survival
Number of days from date of treatment initiation to date of death.
Death will be verified by sites based on death certificates or via
caregiver, relative, or health care provider, and death information
source will be captured in data collection. Surviving patients will be
censored from last date of treatment assessment.
Secondary end points
Disease progression
Number of patients by treatment intervention with MRI/CT
evidence of visible arterial enhancement, radiologic report of
progression, or radiologic report of new tumor growth or
symptomatic/clinical progression.
Time to disease progression
Number of days from date of treatment initiation to date of
documented disease recurrence based on MRI or CT by treatment
intervention, or symptomatic/clinical progression. Patients without
recurrence will be censored from last date of treatment
assessment.
Complication rate
Number of patients by treatment intervention who were
withdrawn due to adverse events prior to introduction of other
therapy.
Time to treatment-limiting adverse events
Number of days from first date of treatment to date of withdrawal
due to adverse event(s) prior to introduction of other therapy.
Patients without treatment-limiting adverse events will be censored
at last date of treatment assessment.
Treatment failure rate
Number of patients by treatment intervention with a finding of
treatment switch, HCC-related hospitalization and emergency room
visit, disease recurrence, or death prior to introduction of other
therapy.
Time to treatment failure
Number of days to first treatment failure overall and by individual
item. Patients without treatment failure will be censored from last
date of treatment assessment.
CT, computed tomography; MRI, magnetic resonance imaging.
Chen et al. BMC Gastroenterology 2011, 11:53
http://www.biomedcentral.com/1471-230X/11/53
Page 3 of 7procedures will comply with Chinese privacy and confi-
dentiality requirements.
Sample size
Sample size requirements for the Chinese regional sites
are approximately 200 patients per site per year between
2008 and 2010 (plus approximately 192 per site for the
first 6 months of 2011) to capture current treatment
and clinical outcomes in HCC, and 100 patients per site
between 2005 and 2007 for historic controls. Pooling of
data across all sites in China will be employed to
describe disease and treatment characteristics across the
country.
Data analysis
To evaluate therapeutic approaches to HCC in China, the
number and percentage of patients using each treatment
(plus any new treatments that are approved and used
within the study period) will be determined for each
study year, in total and stratified by disease stage and
site. Treatment patterns will also be assessed by disease
stage for each study year. Patient characteristics will be
stratified by disease stage and by site for each study year.
To assess therapeutic outcomes, age- and gender-
adjusted rates will be calculated for each study end
point. Cox proportional hazard models will be used for
the time-to-event end points (overall survival and dis-
ease progression) to determine hazard ratios for each
treatment approach, and Kaplan-Meier curves will be
generated. Logistic regression models will be used for
categorical end points (treatment-limiting adverse events
and treatment failure). Covariates for the models will
include disease stage, gender, age, duration of disease,
etiology of disease, liver status, tumor size/spread, surgi-
cal intervention/number of interventions, and number
of comorbidities; analyses w i l lb ec o n d u c t e da tt h es i t e
and country level. The same analysis plan will be
adopted for the evaluation of survival and other clinical
end points with sorafenib versus other therapies, except
that “treatment” will be included as a covariate. Further
analyses will be conducted to evaluate clinical character-
istics and demographics of patients treated with sorafe-
nib versus other treatments for HCC. In addition, data
collected will be used to analyze additional aspects
related to HCC epidemiology and management in China
(Table 2). All tests of statistical significance will be car-
ried out at the 0.05 level.
Loss to follow-up
Throughout the HCC BRIDGE China national study,
patients are expected to leave via loss to follow-up, by
consenting to enter a randomized clinical trial of pri-
mary HCC treatment, or at death. Death certificate
searches or interviews with the patient’s caregiver,
relative, or health care provider will be used to verify
deaths. The inability to verify deaths is expected for 5%
of patients in the study. Sample size calculations have
been adjusted accordingly to account for this level of
missing data for the primary end point of the study.
Results
The number of patients enrolled across the various geo-
graphic regions captured in the global HCC BRIDGE
study is expected to exceed 20,000. For the HCC
BRIDGE China national study, a total of 15 sites across
China have been selected for inclusion at the time of
writing. At present, the anticipated country-wide study
population is approximately 9000 patients (Figure 1).
Discussion
Over the past 3 to 4 decades, China has experienced a
substantial increase in the incidence of HCC [5], and
the country now accounts for more than half of the
world’s cases of this malignancy [2,3]. Nevertheless, in
spite of the huge health care burden of HCC in China,
there has never been a truly geographically representa-
tive study of HCC in this country and active surveillance
is currently lacking. This suggests that the current esti-
mates of the incidence and prevalence of HCC in China
may not be accurate, and that regions with a current
high unmet need and/or a high risk for new HCC cases
may be unidentified.
Table 2 Additional aspects of HCC management for
potential evaluation using data from the HCC BRIDGE
China national study
Outcomes in patient subpopulations
￿ Assessment of treatment use and clinical outcomes among
patients with:
◦ Traditional HCC risk factors, such as hepatitis B or hepatitis C
virus infection (or co-infection), alcoholic liver disease, or
cirrhosis
◦ Diabetes or multiple metabolic disorder
◦ HIV co-infection
￿ Assessment of the impact of underlying disease management on
clinical outcomes in these patients
￿ Evaluation of potential regional/provincial differences in outcomes
among patient subpopulations
Impact of HCC screening
￿ Assessment of influence of screening on:
◦ Treatment allocation and clinical outcomes
◦ Overall survival
◦ Underlying disease
￿ Evaluation of the cost-effectiveness of mandatory HCC screening
Health care access
￿ Evaluation of the level of health care access in different regions/
provinces and association with clinical outcomes
￿ Examination of any potential influence of immigrant/minority
status, risk factor status, and alcohol and drug use on health care
access
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geographically representative epidemiologic study of
H C Ci nC h i n aa n di se x p e c t e dt oi n c l u d em o r et h a n
9000 patients over its course. This study, via its inclusion
of a large number of sites across all 7 traditional regions
of China, will facilitate a thorough assessment of HCC
patient characteristics, treatment allocation, and clinical
outcomes, across the entire country, as well as allowing a
unique analysis of possible regional variations in these
aspects of HCC epidemiology and management. Ultimately,
the study will help determine levels of unmet medical need
and identify regions of high risk for HCC within China.
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Figure 1 Geographic distribution of sites currently included in the HCC BRIDGE China national study.
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of treatment patterns and associated outcomes among
HCC patients in China, the data generated by the HCC
BRIDGE China national study may provide insights into
other aspects of HCC epidemiology and management,
such as the potential role of HCC screening in treat-
ment allocation and outcomes, and possible differences
in clinical outcomes among different HCC patient sub-
populations. Moreover, the study data may further help
address other unanswered questions related to HCC in
China, including questions about the appropriateness of
current standards of care for HCC, the extent of usage
and the impact of traditional Chinese herbal medicine,
and best practices in clinical care for Chinese patients
with HCC. Through these investigations and analyses,
the study also has the potential to inform ongoing
China public health reform, policy, and practice.
The eventual findings of the HCC BRIDGE China
national study will need to be considered in light of the
study’s strengths and weaknesses. The primary strengths
of this study are (1) the large number of patients
included; (2) the geographic representativeness of the
included sites; and (3) the use of real-life clinical prac-
tice data. Additional strengths include the use of centra-
lized data monitoring, cleaning, site queries, and
checking of invalid clinical values, which will enhance
the quality of the collected data, as well as the use of
identified prognostic factors for HCC survival to control
for population differences that may influence treatment
outcomes. The main potential study limitations are (1)
treatment comparisons are performed in patients with-
out prospective randomization methodology; (2) both
academic and nonacademic centers/hospitals are
included, which may result in differing quality of medi-
cal care for enrolled patients; (3) data quality is depen-
dent on the thoroughness of the clinician’s
documentation of medical history, treatment, and out-
comes; and (4) data collection bias is possible since clin-
ical assessments are not conducted at predefined time
points, as in a clinical trial, but at times determined by
clinicians and their patients.
Conclusion
In conclusion, the HCC BRIDGE China national study
represents the first geographically representative study
of HCC in China and will contribute significantly to the
understanding of patterns of HCC therapy use and
related clinical outcomes, as well as knowledge of conti-
nuing unmet needs for HCC.
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